5 Best Medical Stocks to Buy Under $10

3. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Share Price as of February 21: $5.63

Number of Hedge Fund Holders: 32

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a global biotechnology company focused on leveraging its expertise in structure-guided drug design to develop oral small-molecule and protein therapeutics to target difficult-to-treat diseases.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients.

On January 5, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced preliminary, unaudited ORLADEYO® net revenue for Q4 2023. Net revenue for ORLADEYO® increased by 27% y-o-y to $90 million during the quarter with full-year net revenue of nearly $325 million.

As of Q4 2023, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares were held by 32 hedge funds. These hedge funds together held shares worth $383 million.